Castleark Management’s NovoCure NVCR Stock Holding History

Castleark Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-13,245	Closed	-$2.29M	–	359
2020 Q4	$2.29M	Buy	+13,245	New	+$1.81M	0.09%	189
2020 Q2	–	Sell	-79,624	Closed	-$5.36M	–	370
2020 Q1	$5.36M	Sell	79,624 -1,675	-2%	-$132K	0.32%	90
2019 Q4	$6.85M	Sell	81,299 -1,576	-2%	-$127K	0.27%	123
2019 Q3	$6.2M	Buy	+82,875	New	+$6.63M	0.25%	133
2019 Q2	–	Sell	-88,358	Closed	-$4.26M	–	379
2019 Q1	$4.26M	Sell	88,358 -159,155	-64%	-$7.66M	0.16%	167
2018 Q4	$8.29M	Sell	247,513 -106,915	-30%	-$3.91M	0.35%	86
2018 Q3	$18.6M	Sell	354,428 -10,525	-3%	-$419K	0.53%	45
2018 Q2	$11.4M	Sell	364,953 -12,057	-3%	-$335K	0.35%	93
2018 Q1	$8.22M	Sell	377,010 -46,623	-11%	-$1M	0.26%	123
2017 Q4	$8.56M	Sell	423,633 -24,825	-6%	-$478K	0.26%	131
2017 Q3	$8.9M	Buy	+448,458	New	+$8.81M	0.28%	129

Other funds holding NVCR

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Castleark Management's NVCR Position: Q1 2021 in Review

Castleark Management sold out of NovoCure (NVCR) in Q1 2021, closing a stake of 13,245 shares — an estimated $2.29M sold.

Castleark Management first reported a position in NVCR in Q3 2017 and held it in 11 quarters. The position peaked at $18.6M in Q3 2018. 327 funds tracked by Wall St. Rank hold NVCR as of Q1 2021.

Castleark Management reported no remaining NovoCure position as of Q1 2021 after selling out during the quarter.
Castleark Management sold 13,245 NovoCure shares in Q1 2021, an estimated $2.29M.
Castleark Management first reported a position in NovoCure in Q3 2017 and held it in 11 quarters.
Castleark Management's NovoCure position peaked at $18.6M in Q3 2018.
327 funds tracked by Wall St. Rank held NovoCure as of Q1 2021.

Based on Castleark Management's 13F filing for Q1 2021, filed 14 May 2021.